# Submitting Next-Generation Sequencing Data to the Division of Antiviral Products – FDA Guidance

Source: https://www.keypedia.com/guidances/guidance-document/submitting-next-generation-sequencing-data-to-the-division-of-antiviral-products/5f623ca9-5f9b-4728-b634-4e46ac31856c

> FDA guidance document: Submitting Next-Generation Sequencing Data to the Division of Antiviral Products. Issue date: July 01, 2026. Get complete insights and analysis.

---

## Details

- Title: Submitting Next-Generation Sequencing Data to the Division of Antiviral Products
- Communication Type: Guidance Document
- Product Type: devices
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2026-07-01
- Last Changed: 2026-07-01
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2017-D-6821">FDA-2017-D-6821</a>

## Related Documents

- [Submitting Clinical Trial Data to Evaluate the Ability to Operate a Motor Vehicle](https://www.keypedia.com/guidances/guidance-document/submitting-clinical-trial-data-to-evaluate-the-ability-to-operate-a-motor-vehicle/7d2a6f0e-ce89-42d2-bb41-c1b5636ed8dc)
- [Submitting Clinical Trial Datasets to Evaluate the Impact of Immunogenicity on the Pharmacokinetics of a Drug](https://www.keypedia.com/guidances/guidance-document/submitting-clinical-trial-datasets-to-evaluate-the-impact-of-immunogenicity-on-the-pharmacokinetics-of-a-drug/b906dd96-5571-4f8d-81c0-ac787e48c230)
- [Submitting Nonclinical Datasets for Evaluation of Rodent Carcinogenicity Studies of Pharmaceuticals](https://www.keypedia.com/guidances/guidance-document/submitting-nonclinical-datasets-for-evaluation-of-rodent-carcinogenicity-studies-of-pharmaceuticals/5558f50a-6637-45c7-9848-23f5e55738d6)